Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure

Hypertension

Volumn 48, Issue 1, 2006, Pages 93-97

  Perlini, Stefano ^a,c,d,e   Ferrero, Ivana ^a,f   Palladini, Giuseppina ^a   Tozzi, Rossana ^a   Gatti, Chiara ^h   Vezzoli, Monia ^c,d,e   Cesana, Francesca ^a   Janetti, Maria Bianchi ^c,d,e,f   Clari, Francesca ^f   Busca, Giuseppe ^b   Mancia, Giuseppe ^c,d,e,f   Ferrari, Alberto U ^c,f,g  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Centro di Fisiologia Clinica e Ipertensione   (Italy)

^d Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

^e Dipartimento di Medicina Interna e Terapia Medica   (Italy)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h NONE

Author keywords

Heart failure; Hypertrophy; Rats; Receptors, adrenergic alpha; Sympathectomy; Ventricular function, left

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; OXIDOPAMINE; PROPRANOLOL DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ECHOCARDIOGRAPHY; FLOW RATE; HEART DILATATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WEIGHT; LUNG CONGESTION; LUNG WEIGHT; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; SURVIVAL; SYMPATHECTOMY; ABDOMINAL AORTA; ANIMAL; BLOOD PRESSURE; CHEMICAL SYMPATHECTOMY; CONGESTIVE HEART FAILURE; HEART RATE; HYPERTENSION; MALE; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; DOXAZOSIN; HEART FAILURE, CONGESTIVE; HEART RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; OXIDOPAMINE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHECTOMY, CHEMICAL;

EID: 33745982068     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000226859.42064.ea     Document Type: Article

References (18)

1. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724-728.
2. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand. 2003;177:391-398.
3. Mircoli L, Fedele L, Benetti M, Bolla GB, Radaelli A, Perlini S, Ferrari AU. Preservation of the baroreceptor heart rate reflex by chemical sympathectomy in experimental heart failure. Circulation. 2002;106:866-872.
4. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation. 1989;79:872-883.
5. Meyer TE, Chung ES, Perlini S, GR Norton, Woodiwiss AJ, Lorbar M, Fenton RA, Dobson JG Jr. Pressure-overload hypertrophy is associated with attenuated adenosine A1 receptor-mediated antiaadrenergic signaling. Hypertension. 2001;37:862-868.
6. Castellano M, Bohm M. The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension. 1997;29:715-722.
7. Satwani S, Dec GW, Narula J. β-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther. 2004;9:243-255.
8. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, β-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail. 2005;7:710-721.
9. Packer M. Current role of β-adrenergic blockers in the management of chronic heart failure. Am J Med. 2001;110:81-94.
10. Marano G, Palazzesi S, Fadda A, Vergari A, Ferrari AU. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of β-adrenoceptor blockade. J Hypertens. 2002;20:763-769.
11. Marano G, Palazzesi S, Vergari A, Catalano L, Gaudi S, Testa C, Canese R, Carpinelli G, Podo F, Ferrari AU. Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice. Pflugers Arch. 2003;446:429-436.
12. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, Ferrari AU. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension. 2005;46:1213-1218.
13. Chung ES, Perlini S, Fenton RA, Dobson JG Jr, Meyer TE. Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure oveload hypertrophy in the rat. J Hypertens. 1998;16:1813-1822.
14. Ogino K, Cai B, Gu A, Kohmoto T, Yamamoto N, Burkhoff D. Factors contributing to pressure overload-induced immediate early gene expression in adult rat hearts in vivo. Am J Physiol. 1999;277:H380-H387.
15. Ostman-Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Br J Pharmacol. 1995;116:2703-2709.
16. Endoh M, Hiramoto T, Ishihata A, Takanashi M, Inui J. Myocardial α 1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylino-sitol metabolism. Species differences in receptor distribution and the intracellular coupling process in mammalian ventricular myocardium. Circ Res. 1991;68:1179-1190.
17. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb SR, Shah PM, Saunders R, Fletcher R, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
18. ALLHAT Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chorthalidone. JAMA. 2000;283:1967-1975.